Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Cystic fibrosis & COPD: Mucus reprograms immune cells and promotes airway inflammation

No. 59c | 16/11/2021

Scientists of the Translational Lung Research Center Heidelberg (TLRC) and the German Cancer Research Center (DKFZ) have discovered a new link between excessive airway mucus and chronic airway inflammation that is characteristic of cystic fibrosis and chronic obstructive pulmonary disease (COPD). The researchers showed that mucus in the airways reprograms certain cells of the immune system, called macrophages, disrupting their functions and causing them to develop pro-inflammatory properties. In the future, airway macrophages could become the target of novel therapies to treat cystic fibrosis and COPD.

© Patrick J. Lynch, Wikipedia

Lung diseases such as cystic fibrosis and COPD are associated with severe mucus obstruction and chronic inflammation of the airways. Acute inflammatory responses to external stimuli are an important host defence mechanisms of the lung. However, patients with cystic fibrosis and COPD experience persistent inflammation, which causes progressive destruction of lung tissue, which in turn favours recurrent airway infections. Researchers have been unable to explain the cause of the ongoing airway inflammation. "Even in the absence of infection, young children with cystic fibrosis already have chronically inflamed airways. We therefore hypothesized that this chronic inflammation may be triggered by mucus itself," says Prof. Marcus Mall, director of the Department of Pediatric Respiratory Medicine, Immunology and Intensive Care Medicine at Charité - Universitätsmedizin Berlin and co-lead author of the publication.

Mucus alters properties of airway macrophages
TLRC researchers at Heidelberg University Hospital and the German Cancer Research Center Heidelberg (DKFZ) tested the extent to which mucus plugging of the airways affects certain immune cells, so-called macrophages. Macrophages are "phagocytic cells" that eliminate bacteria, viruses, or dead cells and are thereby counteracting chronic inflammation. Surprisingly, the researchers observed that macrophages from the airways of mice with airways obstructed with mucus had pro-inflammatory properties. The diseased mice had been genetically modified to produce increased airway mucus. They serve as an animal model for cystic fibrosis and COPD in humans. "The macrophages from the lungs of these mice no longer fulfilled their function as phagocytic cells and produced pro-inflammatory mediators," explains Michelle Paulsen, PhD, co-first author of the paper. These findings were confirmed by further experiments in which macrophages from healthy mice were exposed to mucus. As a result, the airway macrophages showed the same changes as those isolated from the lungs of the genetically modified mice.

Epigenetic changes reprogram airway macrophages
To explain why airway macrophages that have come into contact with viscous airway mucus show different characteristics than macrophages from healthy airways, the researchers took a closer look at the genetic material of the immune cells. They paid particular attention to the structure and modifications of the DNA in the cell's nucleus. "We were able to show that certain sections of the macrophage genome were altered in such a way that genes for pro-inflammatory mediators were more accessible," summarizes Prof. Christoph Plass, department head at the DKFZ and co-lead author of the publication. The changes in the DNA were not changes related to DNA sequence, but so-called epigenetic changes that influence the structure of the DNA. The observed changes in macrophage DNA caused a loosening of the DNA structure.

Airway macrophages as a target for new therapies
The results of this study show that severe obstruction of the airways with mucus contributes to chronic airway inflammation by reprogramming airway macrophages, which worsens the symptoms in patients with cystic fibrosis and COPD. The study's findings underscore the importance of mucolytic therapies for treating muco-obstructed lung diseases and open up new avenues for research. "In the future, the altered airway macrophages could serve as a target for the development of new anti-inflammatory therapies for cystic fibrosis and COPD," postulates Joschka Hey, PhD, a scientist at DKFZ and co-first author of the paper.

Original publication
Joschka Hey, Michelle Paulsen, Reka Toth, Dieter Weichenhan, Simone Butz, Jolanthe Schatterny, Reinhard Liebers, Pavlo Lutsik, Christoph Plass & Marcus A. Mall. Epigenetic reprogramming of airway macrophages promotes polarization and inflammation in muco-obstructive lung disease. Nature Communications 2021, DOI: 10.1038/s41467-021-26777-9

Press release of the Translational Lung Research Center Heidelberg (TLRC), partner in the German Center for Lung Research (DZL)

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS